Risk of virus-associated cancer in female arthritis patients treated with biological DMARDs-a cohort study

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Risk of virus-associated cancer in female arthritis patients treated with biological DMARDs-a cohort study. / Cordtz, René; Mellemkjaer, Lene; Glintborg, Bente; Hetland, Merete Lund; Madsen, Ole Rintek; Jensen Hansen, Inger Marie; Dreyer, Lene.

In: Rheumatology (Oxford, England), Vol. 55, No. 6, 2016, p. 1017-1022.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Cordtz, R, Mellemkjaer, L, Glintborg, B, Hetland, ML, Madsen, OR, Jensen Hansen, IM & Dreyer, L 2016, 'Risk of virus-associated cancer in female arthritis patients treated with biological DMARDs-a cohort study', Rheumatology (Oxford, England), vol. 55, no. 6, pp. 1017-1022. https://doi.org/10.1093/rheumatology/kew012

APA

Cordtz, R., Mellemkjaer, L., Glintborg, B., Hetland, M. L., Madsen, O. R., Jensen Hansen, I. M., & Dreyer, L. (2016). Risk of virus-associated cancer in female arthritis patients treated with biological DMARDs-a cohort study. Rheumatology (Oxford, England), 55(6), 1017-1022. https://doi.org/10.1093/rheumatology/kew012

Vancouver

Cordtz R, Mellemkjaer L, Glintborg B, Hetland ML, Madsen OR, Jensen Hansen IM et al. Risk of virus-associated cancer in female arthritis patients treated with biological DMARDs-a cohort study. Rheumatology (Oxford, England). 2016;55(6):1017-1022. https://doi.org/10.1093/rheumatology/kew012

Author

Cordtz, René ; Mellemkjaer, Lene ; Glintborg, Bente ; Hetland, Merete Lund ; Madsen, Ole Rintek ; Jensen Hansen, Inger Marie ; Dreyer, Lene. / Risk of virus-associated cancer in female arthritis patients treated with biological DMARDs-a cohort study. In: Rheumatology (Oxford, England). 2016 ; Vol. 55, No. 6. pp. 1017-1022.

Bibtex

@article{06c277f337c148d1987624e153033988,
title = "Risk of virus-associated cancer in female arthritis patients treated with biological DMARDs-a cohort study",
abstract = "OBJECTIVE: To investigate the risk of virus-associated cancer in female arthritis patients ever treated with biological DMARDs (bDMARDs) compared with never bDMARD-treated patients and ever and never treated with bDMARD compared with the general population.METHODS: This was a cohort study that included 13 905 female patients with RA (72%), PsA (12%), AS (4%) or other arthritides (12%) identified in the DANBIO registry. Ever (n = 5647) and never (n = 10 331) bDMARD-treated patients were followed for virus-associated cancers during 2000-11 by linkage to the Danish Cancer Registry. Hazard ratios and standardized incidence ratios (SIRs) were calculated.RESULTS: In total, 24 and 32 virus-associated cancers were identified among ever and never bDMARD users, respectively (hazard ratio = 0.9, 95% CI: 0.7, 1.2). Oropharyngeal (n = 3, SIR = 4.0, 95% CI: 1.3, 12.4) and anal (n = 2, SIR = 2.5, 95% CI: 0.6, 10.0) cancer only occurred among bDMARD-treated patients. SIR was not increased for cervical cancer, either in ever or never bDMARD-treated patients. SIRs for Hodgkin's and non-Hodgkin's lymphomas were increased in never bDMARD-treated patients (SIR = 2.5, 95% CI: 1.5, 4.0).CONCLUSION: bDMARD therapy was not associated with an overall excess of virus-associated cancers in female arthritis patients. The observed increased occurrence of oropharyngeal cancer needs further investigation. Lymphoma incidence was increased in patients unexposed to bDMARD treatment.",
keywords = "Journal Article",
author = "Ren{\'e} Cordtz and Lene Mellemkjaer and Bente Glintborg and Hetland, {Merete Lund} and Madsen, {Ole Rintek} and {Jensen Hansen}, {Inger Marie} and Lene Dreyer",
note = "{\textcopyright} The Author 2016. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oup.com.",
year = "2016",
doi = "10.1093/rheumatology/kew012",
language = "English",
volume = "55",
pages = "1017--1022",
journal = "Rheumatology",
issn = "1462-0324",
publisher = "Oxford University Press",
number = "6",

}

RIS

TY - JOUR

T1 - Risk of virus-associated cancer in female arthritis patients treated with biological DMARDs-a cohort study

AU - Cordtz, René

AU - Mellemkjaer, Lene

AU - Glintborg, Bente

AU - Hetland, Merete Lund

AU - Madsen, Ole Rintek

AU - Jensen Hansen, Inger Marie

AU - Dreyer, Lene

N1 - © The Author 2016. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

PY - 2016

Y1 - 2016

N2 - OBJECTIVE: To investigate the risk of virus-associated cancer in female arthritis patients ever treated with biological DMARDs (bDMARDs) compared with never bDMARD-treated patients and ever and never treated with bDMARD compared with the general population.METHODS: This was a cohort study that included 13 905 female patients with RA (72%), PsA (12%), AS (4%) or other arthritides (12%) identified in the DANBIO registry. Ever (n = 5647) and never (n = 10 331) bDMARD-treated patients were followed for virus-associated cancers during 2000-11 by linkage to the Danish Cancer Registry. Hazard ratios and standardized incidence ratios (SIRs) were calculated.RESULTS: In total, 24 and 32 virus-associated cancers were identified among ever and never bDMARD users, respectively (hazard ratio = 0.9, 95% CI: 0.7, 1.2). Oropharyngeal (n = 3, SIR = 4.0, 95% CI: 1.3, 12.4) and anal (n = 2, SIR = 2.5, 95% CI: 0.6, 10.0) cancer only occurred among bDMARD-treated patients. SIR was not increased for cervical cancer, either in ever or never bDMARD-treated patients. SIRs for Hodgkin's and non-Hodgkin's lymphomas were increased in never bDMARD-treated patients (SIR = 2.5, 95% CI: 1.5, 4.0).CONCLUSION: bDMARD therapy was not associated with an overall excess of virus-associated cancers in female arthritis patients. The observed increased occurrence of oropharyngeal cancer needs further investigation. Lymphoma incidence was increased in patients unexposed to bDMARD treatment.

AB - OBJECTIVE: To investigate the risk of virus-associated cancer in female arthritis patients ever treated with biological DMARDs (bDMARDs) compared with never bDMARD-treated patients and ever and never treated with bDMARD compared with the general population.METHODS: This was a cohort study that included 13 905 female patients with RA (72%), PsA (12%), AS (4%) or other arthritides (12%) identified in the DANBIO registry. Ever (n = 5647) and never (n = 10 331) bDMARD-treated patients were followed for virus-associated cancers during 2000-11 by linkage to the Danish Cancer Registry. Hazard ratios and standardized incidence ratios (SIRs) were calculated.RESULTS: In total, 24 and 32 virus-associated cancers were identified among ever and never bDMARD users, respectively (hazard ratio = 0.9, 95% CI: 0.7, 1.2). Oropharyngeal (n = 3, SIR = 4.0, 95% CI: 1.3, 12.4) and anal (n = 2, SIR = 2.5, 95% CI: 0.6, 10.0) cancer only occurred among bDMARD-treated patients. SIR was not increased for cervical cancer, either in ever or never bDMARD-treated patients. SIRs for Hodgkin's and non-Hodgkin's lymphomas were increased in never bDMARD-treated patients (SIR = 2.5, 95% CI: 1.5, 4.0).CONCLUSION: bDMARD therapy was not associated with an overall excess of virus-associated cancers in female arthritis patients. The observed increased occurrence of oropharyngeal cancer needs further investigation. Lymphoma incidence was increased in patients unexposed to bDMARD treatment.

KW - Journal Article

U2 - 10.1093/rheumatology/kew012

DO - 10.1093/rheumatology/kew012

M3 - Journal article

C2 - 26912584

VL - 55

SP - 1017

EP - 1022

JO - Rheumatology

JF - Rheumatology

SN - 1462-0324

IS - 6

ER -

ID: 179162195